In primary prevention of atherosclerotic disease, it is difficult to decide when medical treatment should be initiated. The main goal of the study was to compare different guidelines for coronary heart disease (CHD) risk assessment and initiation of lipid-lowering therapy. RESULTS: Guidelines could be applied to different subsets of the cohort, ranging from 22% (PROCAM) to 95% of the cohort (revised Sheffield table). All guidelines (except PROCAM) could be applied to a total of 62 patients. Guidelines predicted 20% risk for developing CHD over 10 years in 53% (NCEP ATP III), 26% (European) and 32% (British), while Framingham predicted this risk level in 34%. CHD risk was estimated to be 3%/year in 5% according to Sheffield, while Framingham predicted this risk in 13%. Lipid-lowering drug therapy is recommended in 52% by NCEP ATP III, while European, British, and Sheffield guidelines recommend this in 26%, 35%, and 5%, respectively. CONCLUSIONS: Guidelines for assessing CHD risk and lipidlowering therapy differ greatly. Therefore, these algorithms must be used with caution.
T here is no doubt that decreasing blood pressure and/ or serum cholesterol is effective in the primary prevention of coronary heart disease (CHD). The most reassuring findings about the benefits and safety of lipidlowering medical treatment in primary prevention came from the West of Scotland Coronary Prevention Study (WOSCOPS) 1 and the Air Force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPs). 2 If, however, the absolute risk for atherosclerosis is low, primary prevention strategies using drug therapy must be questioned, because they may impose an unjustified financial burden, and side effects may balance benefits in the long run. It is therefore of utmost importance to identify subjects who will benefit most from primary prevention. A number of guidelines have therefore been developed to identify such subjects. The Framingham Heart Study identified several independent risk factors for CHD, including age, gender, blood pressure, total cholesterol, high-density lipoprotein cholesterol, smoking, diabetes and electrocardiogram (ECG)-left ventricular hypertrophy. 3 The U.S. National Cholesterol Education Program (Adult Treatment Panel III) (NCEP ATP III) guidelines, 4 the joint European Societies guidelines, 5, 6 the joint British guidelines, 7 and the revised Sheffield table 8 use Framingham data to predict CHD risk and/or to recommend lipid-lowering therapy. The Munster Heart Study calculator, based on different epidemiological data, includes triglyceride concentration and family history, but can only be applied to men. 9 All of these guidelines agree that risk factors are multiplicative, that risk is highest in subjects with several risk factors, and that specific drug therapy should only be initiated if absolute risk exceeds a certain threshold. However, these guidelines disagree on the selection and weighting of risk factors and on the risk level above which drug therapy is recommended (Appendix A). The threshold for such therapy is 20% over 10 years according to the joint European Societies guidelines and 15% over 10 years according to the joint British guidelines. The revised Sheffield 
METHODS
One hundred consecutive patients without any clinical evidence of cardiovascular disease and without any lipidlowering medication referred to our outpatient lipid and diabetes clinic were included in this study. Lack of hyperlipidemia was not a reason for exclusion. Each patient was interviewed using a standardized questionnaire concerning hypertension, antihypertensive treatment, diabetes mellitus, smoking, and family history of coronary heart disease, and was examined by a physician.
Blood pressure was measured after a 5-minute rest to the nearest 5 mmHg by mercury sphygmomanometry. Diabetes mellitus was defined according to World Health Organization criteria. 12 Most algorithms only allow the evaluation of patients with specific characteristics (for example: in PROCAM only men aged 40 to 65 years can be evaluated, and in the Joint European guidelines, total cholesterol must be between 125 and 325 mg/dL). If patients have parameters outside the specific range of the individual algorithms, the algorithm cannot be applied. Patients in whom any algorithm could not be applied (except PROCAM) were excluded.
Agreement between different guidelines was evaluated using calculation of kappa (k). Strength of agreement was considered poor for k < 0.20, fair for k = 0.21 to 0.40, moderate for k = 0.41 to 0.60, good for k = 0.61 to 0.80, and very good for k = 0.81 to 1.00. 15 Patients gave informed consent. A potential conflict of interest does not exist.
RESULTS
The characteristics of the patients enrolled in this study are shown in Table 1 . There was a high proportion of patients with diabetes (35%; type 1, N = 7; type 2, N = 28) and with a family history of premature CHD (45%).
The Framingham risk equation was applicable to 87 patients, the U.S. NCEP ATP III algorithm to 93 patients, the joint European Societies guidelines to 81, the joint British guidelines to 72 patients, and the revised Sheffield table to 95 patients. The Munster Heart Study calculator (PROCAM) was applicable to only 22 patients, because the PROCAM study applies only to men aged 40 to 65 years. NCEP ATP III recommended lipid-lowering drug treatment in 32 patients (52%). Medical treatment was recommended by the joint European Societies guidelines in 16 (26%) and by the joint British guidelines in 22 patients (35%), while only 3 patients (5%) met the revised Sheffield table criteria for lipid-lowering medication (Fig. 1) . Only 11 and 14 patients requiring drug therapy according to the joint European Societies guidelines and the joint British guidelines, respectively, would receive lipid-lowering medication according to NCEP ATP III.
Stratification by gender did not reveal significant differences between males and females concerning risk estimates. However, lipid-lowering drug treatment was recommended by NCEP ATP III in 15 of 25 females (60%) but in only 17 of 37 males (46%), while the other guidelines recommended lipid-lowering therapy more often in men (European 35%, British 46%, Sheffield 5%) than in women (European 12%, British 20%, Sheffield 4%).
We also evaluated the comparability of guidelines in the subgroup of patients without diabetes, which revealed similar results, although agreement in risk estimate between NCEP ATP III and 
DISCUSSION
This study shows that algorithms for CHD risk assessment and guidelines for lipid-lowering drug therapy vary widely. Patients who are estimated to be at considerable risk for developing CHD according to one guideline are considered low-risk according to other guidelines. Compared to the original Framingham risk equation, which was used a gold standard, the joint British guidelines perform most closely. Guidelines also differ in their recommendation concerning lipid-lowering drug therapy. Finally, there are a number of patients for whom current guidelines cannot be applied, because guidelines can only be used if raw data are within prespecified ranges (Appendix A).
Our results, obtained in a specialized segment of the German population, confirm previous studies performed in the U.K. 10, 11 and extend the evidence to high-risk patients in Germany. In these previous studies, guidelines were also not applicable to all subjects and resulted in different risk estimates and different recommendations concerning lipidlowering drug therapy. If algorithms are to be useful, they should be widely applicable. In contrast to our study and the study by Durrington et al., 10 patients with parameters outside the range of validity were placed in the nearest applicable section of the algorithms in the study by Wierzbicki et al. 11 Therefore, applicability of algorithms in our study was less than that described by Wierzbicki et al. 11 However, the Framingham risk equation, the U.S. NCEP ATP III algorithm, and the revised Sheffield table were still widely applicable (>87%). The Munster Heart Study Calculator performs worst in this respect, because it could be applied only to 22% of the subjects (middle-aged men). This, however, is related to our study population. If PROCAM is applied to other relevant segments of the population, applicability will increase. Guidelines are based on epidemiological studies. There are only a very limited number of epidemiological studies available that are large and long enough to allow CHD risk to be estimated. The U.S. NCEP ATP III algorithm, the joint European Societies guidelines, the joint British guidelines, and the revised Sheffield table are all based on data from the Framingham Heart Study. The Munster Heart Study (PROCAM) Calculator in contrast is based on a separate set of epidemiological data. Thus, although most guidelines are based on the same epidemiological data, risk estimates differ. If the original Framingham risk equation is used as a gold standard for calculating coronary heart disease risk, the joint British guidelines reflect risk assessment best (k = 0.81). The revised Sheffield table, although it is also based on the Framingham data, compared poorly with the Framingham equation (k < 0.20). This is not related to the fact that this guideline was applied to a German cohort, because a very similar finding was described by Durrington et al. 10 and Wierzbicki et al. 11 in U.K. subjects.
The PROCAM calculator is based on a separate set of epidemiological data, and risk estimates differed considerably from the results of the Framingham risk equation. Possible explanations for the observed differences relate to the fact that the epidemiological data used to develop the algorithm were collected in different societies and at different times. The Munster Heart Study was initiated in 1979, recruiting subjects from Munster and the Northern Ruhr Area (Germany), whereas the Framingham Heart Study was started about 30 years earlier.
Furthermore, even if the same epidemiological data are used, the guidelines depend very much on the model used to analyze the raw data. The model will, to a certain point, determine which parameters remain in the analysis and which will be excluded. In the end, all guidelines for assessing CHD risk represent simplifications with a certain selection and weighting of risk factors. Appendix A, comparing the different guidelines, for example, shows that diabetic patients are handled quite differently in different guidelines.
The threshold above which lipid-lowering medical therapy is recommended varies between 15% over 10 years to 3% per year. The U.S. NCEP guidelines do not state a threshold of CHD risk. Clinical assessment of previous NCEP guidelines demonstrated that people at substantially lower risk thresholds would be treated compared to the European or British recommendations.
16±18
This is confirmed in our study and extended to the NCEP ATP III guidelines. Depending on the guideline, between 52% (U.S. NCEP ATP III) and 5% (revised Sheffield table) of the patients should be treated with lipid-lowering drugs. While the European guidelines recommend lipid-lowering drug therapy more often in men, NCEP ATP III recommends such therapy more often in women. The discrepancy between the U.S. NCEP ATP III guidelines on the one hand and the European guidelines on the other hand is related to several facts. Most importantly, ATP III defines diabetes as a CHD risk equivalent (i.e., diabetic patients carry a risk for major coronary events >20% per 10 years). Consensus recommendations such as the U.S. NCEP ATP III guidelines are not based only on one set of data (such as Framing- 
21±26
These tests indicate whether early forms of atherosclerosis are present. However, the usefulness of these parameters is still under debate, and it is unclear in which patients these exams should be performed and how results should be incorporated into existing guidelines. To optimize guidelines in the long run, new epidemiological information from studies such as the MONICA Augsburg cohort study 27 or the Women's Health Initiative 28 must be incorporated. Although these newer studies generally confirm the risk factors established in the Framingham study, the importance of individual risk factors is different (for example, the risk associated with diabetes is higher in MONICA than in Framingham). There is, however, neither an established method for incorporating such new information into existing guidelines nor an easy way to validate the modified guidelines.
The limitations of this study should be noted. First, the sample size is small, which reduces the power of the study. Any results relating to subgroups (gender, diabetic/ nondiabetic patients) must be interpreted with caution. In addition, the single-site study design makes the study sensitive to local differences in the study population. Furthermore, our results may be limited by a selection and referral bias. Since the study was performed in an outpatient lipid and diabetes clinic of a university hospital, we had a high proportion of diabetic patients and patients with a positive family history for premature CHD. Thus, our findings are restricted to this segment of the population. It may well be that guidelines agree to a much higher extent and are more widely applicable in other segments of the population.
This study confirms that guidelines for assessing CHD risk and lipid-lowering drug therapy differ significantly, despite the fact that most guidelines are based on the same epidemiological data. However, despite these differences the guidelines agree that risk factors are multiplicative and that risk is highest in subjects with several risk factors. The observed differences also provide the impetus for developing new consensus recommendations that take into account the wide range of opinions that exist in the community.
